Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtrer
Plus de filtres








Gamme d'année
1.
Rev. med. nucl. Alasbimn j ; 9(37)July 2007. ilus, tab
Article de Anglais | LILACS | ID: lil-474918

RÉSUMÉ

Objective To evaluate the usefulness of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose (FDG-PET) in the follow-up of endometrial cancer patients with suspicion of recurrence due to elevated serum tumour markers and suggestive conventional imaging findings. Material and methods A retrospective review was conducted of 17 FDG-PET studies performed in 11 patients with a previous diagnosis of endometrial cancer (6 patients underwent 2 studies) between April 2002 and October 2005. Mean age of patients was 63.4 yrs (range, 52-69 yrs), and mean time since diagnosis was 56 months (range, 11 months - 12 yrs). Initially, 7 patients were in stage I, 3 in stage III, and 1 in stage IV (FIGO classification). Histologically, they corresponded to 8 endometrioid and 3 non-endometrioid cancers. Results FDG-PET showed infradiaphragmatic uptake in three patients and disseminated disease in seven; findings were negative in one patient. Computed tomography (CT, n=7) or magnetic resonance (MRI, n=7) images revealed infradiaphragmatic lesions in five patients and visceral lesions in two. All patients showed elevated serum tumour markers (CA125, n=9; CA19.9, n=2; CA15.3, n=2). FDG-PET results modified the information provided by conventional imaging techniques in seven patients and provided no additional information in the remaining four. There was histological confirmation of lesions in two patients. Nine patients were clinically followed up, including imaging studies (mean follow-up, 8.7 months; range, 3-20 months).


Sujet(s)
Femelle , Adulte d'âge moyen , Humains , Adénocarcinome , Carcinome adénosquameux , Tumeurs de l'endomètre , Tumeurs de l'utérus , Tomoscintigraphie/méthodes , Complications postopératoires , Complications postopératoires/prévention et contrôle , Études rétrospectives , Études de suivi , Marqueurs biologiques tumoraux/analyse , Tumeurs de l'endomètre/chirurgie , Tumeurs de l'utérus/chirurgie , Radiopharmaceutiques , Récidive/prévention et contrôle
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE